Search Results 431-440 of 17074 for nivolumab

1. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

   Lack of response to therapy with a PD-1- or PD-L1-targeting monoclonal antibody (pembrolizumab, nivolumab, etc.) after at least 18 weeks of therapy OR ...

2. Gastroenterology and Hepatology - Clinical trials

   In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls. Jacksonville, Fla. The purpose of this ...

3. Where we are with gastric and esophageal cancers - Mayo Clinic

   Similarly, the U.S. FDA approved the combination of chemotherapy with another checkpoint inhibitor, nivolumab, in metastatic gastric adenocarcinoma. The ...

4. Clinical Trials - ICI And Response In Autoimmunity

   ... nivolumab, cemiplimab, atezolimumab, durvalumab, or avelumab. Presence of inflammatory arthritis defined by: Provider documents inflammatory arthritis in one ...

5. FOG-001 In Locally Advanced Or Metastatic Solid Tumors - Mayo Clinic

   ... Nivolumab * Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases. * MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1 ...

6. Early Identification Of Chemotherapy Induced Cardiac Toxicity - Mayo Clinic

   Immune checkpoint inhibitors (Ipilimumab, Nivolumab, Pembrolizumab). Exclusion Criteria: Coronary artery disease. Significant (more than mild) valvular ...

7. Gastroenterology and Hepatology - Clinical trials

   In-home Versus In-Clinic Subcutaneous Nivolumab Administration Through Connected And Remote Cancer CARE Beyond Walls. Jacksonville, Fla. The purpose of this ...

8. Study Comparing CB-839 with Cabozantinib vs. Cabozantinib with Placebo in Patients with Metastatic Renal Cell Carcinoma - Mayo Clinic

   the combination regimen of nivolumab + ipilimumab. Exposure to a prior treatment regimen for ≥4 weeks is considered a prior line of therapy, regardless of ...

9. Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis - Mayo Clinic

   About this study. The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks ...

10. Mayo Clinic Q and A: Treatment for liver cancer

    The U.S. Food and Drug Administration recently approved a form of immunotherapy with a drug called nivolumab for liver cancer. Immunotherapy works by ...